Streamlined and focused
24/11/21 -"This looks to be the new motto of Merck’s refurbished R&D pipeline. The strong cut in clinical programmes (50% up to 11/11/2021) has been quietly done. This reminds us of 2014/15, when Merck did ..."
Pages
75
Language
English
Published on
24/11/21
You may also be interested by these reports :
29/10/25
The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, ...
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...